United States · Funded startup
Funding summaryUpdated 26 Oct 2026
$1.4Braised across 4 rounds since 2011, from 4 sources
Each circle is a round, placed by date and sized by amount. The line above is the running total.
Source recorded
RA Capital Management
Wellington Management
Perceptive Advisors
Redmile Group
Tavistock Life Sciences
Partner Fund Management (PFM)From a historical funding recordSEC filing: $50M sold, first sale Nov 2014
F-Prime Capital
Casdin Capital
Third Rock Ventures
Nextech InvestFrom a historical funding recordSEC filing: $23M sold, first sale Jan 2014
Reported by blueprintmedicines.com
From the SEC filings it signed: 4 on the team.
On the board, as filediAlexis S. BorisyDaniel S. LynchDavid S. SchenkeinNicholas S. LydonStephen S. KnightThilo S. Schroeder
The busiest backers across the latest rounds. A filled square is a round they joined; a dark one, a round they led.
RA Capital ManagementWellington ManagementPerceptive AdvisorsF-Prime CapitalRedmile GroupThird Rock VenturesFidelity BiosciencesCasdin CapitalNextech InvestSabby CapitalMissing a round, or an investor who was in one? Tell us.
Blueprint Medicines's investors include RA Capital Management, Wellington Management, Perceptive Advisors, F-Prime Capital and Redmile Group, and 9 more on record.
Blueprint Medicines has raised $1.4B across 4 rounds since 2011.
Blueprint Medicines's most recent round was an Undisclosed round of $1.3B in Jun 2022.
Its most recent round, $1.3B in Jun 2022, is also its largest on record.
Blueprint Medicines's first round on record, in Apr 2011, was backed by F-Prime Capital, Third Rock Ventures and Fidelity Biosciences.
Blueprint Medicines's latest named round is an Undisclosed round, in Jun 2022.
Blueprint Medicines is based in the United States.
In the same sector, and raised in the last eighteen months.
Search every investor by what they have actually funded, then narrow to your stage and market. Free.
United States · 
